Results of the TUXEDO-01 study

Prof Rupert Barsch, medical oncologist at the Medical University of Vienna, discusses with Prof François Duhoux, medical oncologist and head of clinic of the department of oncology at the Cliniques Universitaires in Brussels, on the poster on the TUXEDO-01 study that was presented during one of the poster sessions at SABCS 2023.  

The TUXIDO-01 trial investigated the role of T-DXd in 15 patients with metastatic HER2+ breast cancer and active brain metastasis, defined as newly diagnosed or progressing after prior local therapy. The study revealed a high response rate of approximately 75%. An update with longer median follow-up showed a median PFS of 21 months, consistent with findings from the joint analysis of DESTINY-Breast-01, 02, and 03 trials. Median OS was not reached, and patients maintained neurocognitive functioning and quality of life during treatment. While the results are promising, the small, single-arm nature of the study requires consideration. The findings suggest that T-DXd could be a valid alternative to tucatinib in this specific patient population. The final publication will provide additional details on post-progression treatments, including local therapy, continued T-DXd, and alternative regimens such as trastuzumab or tucatinib combinations.

Reference:

Hurvitz S. et al., HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer –   SABCS 2023, #GS01-10